export default {
	en: {
		app: {
			name: 'ASH Microsite 2023',
		},
		home: {
			title: 'Our<br />Pipeline',
			footer: {
				jobCode: 'UNB-EM-0239 November 2023',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
			},
		},
		titles: {
			trials: {
				lymphoma: 'Lymphoma',
				myleoma: 'Myleoma',
				'classical-hematology': 'Classical Hematology',
				'solid-tumor': 'Solid Tumor',
			},
			cards: {
				'olympia-2':
					'<strong>OLYMPIA-2</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-5':
					'<strong>OLYMPIA-5</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-1': '<strong>OLYMPIA-1</strong> Odronextamab (CD20xCD3 Bispecific)',
				'olympia-3':
					'<strong>OLYMPIA-3</strong> Odronextamab (CD20xCD3 Bispecific) + Chemotherapy',
				'olympia-4': '<strong>OLYMPIA-4</strong> Odronextamab (CD20xCD3 Bispecific)',
				'elm-2': '<strong>ELM-2</strong> Odronextamab (CD20xCD3 bispecific)',
				'elm-1': '<strong>ELM-1</strong> Odronextamab (CD20xCD3 bispecific)',
				'athena-1':
					'<strong>ATHENA-1</strong> Odronextamab (CD20xCD3 bispecific) + REGN5837 (CD22xCD28 bispecific)',
				'clio-1':
					'<strong>CLIO-1</strong> Odronextamab (CD20xCD3 bispecific) + Cemiplimab (PD-1 monoclonal)',
				orchid: '<strong>ORCHID</strong> Non-interventional real-world experience',
				flora: '<strong>FLORA</strong> Non-interventional real-world experience',
			},
		},
		misc: {
			clinicalTrials: 'Clinical trials',
			explore: 'Explore',
			back: 'Back',
			backToTrials: 'Back To Trials',
			phase: 'Phase',
			nonInterventional: 'Non-Interventional',
			seeTrialInfo: 'See Trial Info',
			seeClincialGov: 'See ClinicalTrials.gov',
			noPdf: 'No Trial card PDF found. Please try again later.',
		},
		trials: {
			footer: {
				meta: 'Odronextamab is an investigational drug and has not been fully evaluated by any regulatory authority.',
				jobCode: 'UNB-EM-0239. November 2023',
				enclosed:
					'The enclosed materials are being provided in response to your unsolicited request and are for your information only. The product discussed herein is an investigational agent and has not been fully evaluated or approved by the US Food and Drug Administration or any other regulatory agency worldwide. Reactive Use Only.',
				copyright: '&copy; 2023 Regeneron Pharmaceuticals, Inc. All Rights Reserved.',
			},
		},
	},
};
